Arbutus Biopharma (ABUS) executive compensation, 2026 proxy

Lindsay Androski, President and Chief Executive Officer, was paid $1.4M in 2025.

Filed
April 14, 2026
Annual meeting
May 26, 2026
Pay year
2025
Named executives
4
CEO total pay
$1.4M2025
CEO Base Salary
$437,750For fiscal 2025
CEO Target Bonus
45%Of annual base salary
CFO Base Salary
$359,849For fiscal 2025

How Androski was paid

$1.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary32%Option awards52%Non-equity incentive16%

Named executive officers

ExecutiveTotal
Lindsay AndroskiPresident and Chief Executive Officer$1,369,013
Tuan NguyenChief Financial Officer$2,416,995
Michael McElhaughFormer Interim President and Chief Executive Officer$3,578,150
David C. HastingsFormer Chief Financial Officer$2,218,362

What changed and why

  • Lindsay Androski became President and Chief Executive Officer effective February 25, 2025.
  • Tuan Nguyen was appointed as Chief Financial Officer effective March 28, 2025.
  • Michael McElhaugh and David C. Hastings departed the Company during 2025.
  • 110%Named executive officers received annual incentive cash bonuses equal to 110 percent of target.
  • $515KBase salaries for 2025 were set at $515,000 for Ms. Androski and $475,000 for Mr. Nguyen.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.